| Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial LB Leypoldt, B Besemer, AM Asemissen, M Hänel, IW Blau, M Görner, ... Leukemia 36 (3), 885-888, 2022 | 58 | 2022 |
| Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma LB Leypoldt, D Tichy, B Besemer, M Hänel, MS Raab, C Mann, M Munder, ... Journal of Clinical Oncology 42 (1), 26-37, 2024 | 48 | 2024 |
| Post-vaccination anti-SARS-CoV-2-antibody response in patients with multiple myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment S Ghandili, M Schönlein, M Lütgehetmann, J Schulze zur Wiesch, ... Cancers 13 (15), 3800, 2021 | 36 | 2021 |
| Bone marrow-resident Vδ1 T cells co-express TIGIT with PD-1, TIM-3 or CD39 in AML and myeloma F Brauneck, P Weimer, J Schulze zur Wiesch, K Weisel, L Leypoldt, ... Frontiers in medicine 8, 763773, 2021 | 28 | 2021 |
| Current treatment approaches to newly diagnosed multiple myeloma S Ghandili, KC Weisel, C Bokemeyer, LB Leypoldt Oncology Research and Treatment 44 (12), 690-699, 2021 | 21 | 2021 |
| Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma: Planned interim analysis of the GMMG-Concept Trial K Weisel, B Besemer, M Haenel, R Lutz, C Mann, M Munder, M Goerner, ... Blood 140 (Supplement 1), 1836-1838, 2022 | 11 | 2022 |
| Lymphocytopenia and anti-CD38 directed treatment impact the serological SARS-CoV-2 response after prime boost vaccination in patients with multiple myeloma S Ghandili, M Schönlein, C Wiessner, H Becher, M Lütgehetmann, ... Journal of Clinical Medicine 10 (23), 5499, 2021 | 11 | 2021 |
| Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study M Schönlein, V Wrage, S Ghandili, SC Mellinghoff, TT Brehm, LB Leypoldt, ... Cancer Cell 40 (6), 581-583, 2022 | 8 | 2022 |
| Updated interim analysis of the gmmg-concept trial investigating isatuximab, carfilzomib, lenalidomide, and dexamethasone (isa-krd) in front-line treatment of high-risk … L Leypoldt, B Besemer, AM Asemissen, M Hänel, IW Blau, M Görner, ... ONCOLOGY RESEARCH AND TREATMENT 44, 20-21, 2021 | 8 | 2021 |
| VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience S Ghandili, D Alihodzic, C Wiessner, C Bokemeyer, K Weisel, LB Leypoldt Annals of Hematology 102 (1), 117-124, 2023 | 3 | 2023 |
| Severe Cryoglobulinemic vasculopathy and underlying monoclonal Gammopathy: the importance of identifying and targeting the underlying plasma cell clone in diagnosis and treatment LB Leypoldt, S Ghandili, SW Schneider, C Iking-Konert, C Bokemeyer, ... Archives of Clinical and Biomedical Research 5 (4), 556-568, 2021 | 2 | 2021 |
| Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies MJ Rees, M D'Agostino, LB Leypoldt, S Kumar, KC Weisel, F Gay American Society of Clinical Oncology Educational Book 44 (3), e433520, 2024 | 1 | 2024 |
| IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice D Krzikalla, A Laschtowitz, L Leypoldt, C Gottwick, P Averhoff, ... Cellular and Molecular Gastroenterology and Hepatology 17 (1), 79-91, 2024 | 1 | 2024 |
| Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG … LB Leypoldt, M Gavriatopoulou, B Besemer, H Salwender, MS Raab, ... Cancers 15 (18), 4667, 2023 | 1 | 2023 |
| P926: daratumumab, bortezomib and dexamethasone for treatment of patients with relapsed or refractory multiple myeloma and severe renal impairment: results from the phase 2 … L Leypoldt, M Gavriatopoulou, B Besemer, H Salwender, MS Raab, ... HemaSphere 6, 816-817, 2022 | 1 | 2022 |
| Interferon-gamma and CTLA-4 drive liver-induced systemic CD4 T cell tolerance D Krzikalla, A Laschtowitz, L Leypoldt, D Schwinge, C Schramm, A Lohse, ... Journal of Hepatology 73, S82, 2020 | 1 | 2020 |
| Untersuchung von Mechanismen der hepatischen Immuntoleranz im Tiermodell der Experimentellen Autoimmunen Enzephalomyelitis LB Leypoldt Staats-und Universitätsbibliothek Hamburg Carl von Ossietzky, 2019 | 1 | 2019 |
| Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma LB Leypoldt, D Tichy, B Besemer, M Hanel, MS Raab, C Mann, M Munder, ... Future Oncology, 1-15, 2024 | | 2024 |
| BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report L Cords, C Schaefers, A Kamili, C Hoffmann, S Cichutek, F Haag, ... Haematologica 109 (9), 3071, 2024 | | 2024 |
| P-248 CRISPR-Based Functional Genomics Studies Identify Mechanisms of Multiple Myeloma (MM) Cell Response to vs. Resistance Against Novel Pharmacological Mutant-Specific KRAS … T Steinbrunn, R Shirasaki, O Dashevsky, H Tang, S Yamano, PJ Teoh, ... Clinical Lymphoma Myeloma and Leukemia 24, S180-S181, 2024 | | 2024 |
